---
title: "Shandong Sinobioway Biomedicine Co.,Ltd. (002581.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002581.SZ.md"
symbol: "002581.SZ"
name: "Shandong Sinobioway Biomedicine Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-22T00:03:01.972Z"
locales:
  - [en](https://longbridge.com/en/quote/002581.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002581.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002581.SZ.md)
---

# Shandong Sinobioway Biomedicine Co.,Ltd. (002581.SZ)

## Company Overview

Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.wmm.bio](https://www.wmm.bio) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.58)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 156 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -9.17% |  |
| Net Profit YoY | 8.74% |  |
| P/B Ratio | 1.75 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3147473744.46 |  |
| Revenue | 282796936.15 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.23% | D |
| Profit Margin | -47.17% | E |
| Gross Margin | 13.52% | D |
| Revenue YoY | -9.17% | D |
| Net Profit YoY | 8.74% | C |
| Total Assets YoY | -3.60% | D |
| Net Assets YoY | -3.70% | D |
| Cash Flow Margin | 168.83% | B |
| OCF YoY | -9.17% | D |
| Turnover | 0.13 | E |
| Gearing Ratio | 8.89% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Sinobioway Biomedicine Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-9.17%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "8.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.75",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3147473744.46",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "282796936.15",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.23%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-47.17%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "13.52%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-9.17%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "8.74%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.60%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.70%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "168.83%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-9.17%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.13",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "8.89%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -22.41 | 192/215 | - | - | - |
| PB | 1.66 | 60/215 | 2.88 | 2.70 | 2.58 |
| PS (TTM) | 10.57 | 187/215 | 21.88 | 19.30 | 17.53 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002581.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002581.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002581.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002581.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**